Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation

Journal of Virology

Volumn 85, Issue 22, 2011, Pages 11725-11731

  Alam, S Munir ^a   Liao, Hua Xin ^a   Dennison, S Moses ^a   Jaeger, Frederick ^a   Parks, Robert ^a   Anasti, Kara ^a   Foulger, Andrew ^a   Donathan, Michele ^a   Lucas, Judith ^a   Verkoczy, Laurent ^a   Nicely, Nathan ^a   Tomaras, Georgia D ^a   Kelsoe, Garnett ^a   Chen, Bing ^b   Kepler, Thomas B ^a   Haynes, Barton F ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ASPARAGINE; ASPARTIC ACID; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY 2F5; NEUTRALIZING ANTIBODY; PEPTIDE; PROTEIN; VIRUS ANTIBODY;

ALLELE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; GENETIC VARIABILITY; GERM LINE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; VH 2-5 GENE;

ALLELES; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; COMPLEMENTARITY DETERMINING REGIONS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; PROTEIN BINDING;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80655143478     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05680-11     Document Type: Article

References (48)

1. Alam, S. M., et al. 2007. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 178:4424-4435.
2. Alam, S. M., et al. 2009. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. U. S. A. 106:20234-20239.
3. Alam, S. M., et al. 2008. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J. Virol. 82:115-125.
4. Berman, J. E., and F. W. Alt. 1990. Human heavy chain variable region gene diversity, organization, and expression. Int. Rev. Immunol. 5:203-214.
5. Cardoso, R. M., et al. 2005. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22:163-173.
6. Clarke, S. H., et al. 1985. Inter- and intraclonal diversity in the antibody response to influenza hemagglutinin. J. Exp. Med. 161:687-704.
7. Cook, G. P., and I. M. Tomlinson. 1995. The human immunoglobulin VH repertoire. Immunol. Today 16:237-242.
8. Cook, G. P., et al. 1994. A map of the human immunoglobulin VH locus completed by analysis of the telomeric region of chromosome 14q. Nat. Genet. 7:162-168.
9. Dal Porto, J. M., A. M. Haberman, G. Kelsoe, and M. J. Shlomchik. 2002. Very low affinity B cells form germinal centers, become memory B cells, and participate in secondary immune responses when higher affinity competition is reduced. J. Exp. Med. 195:1215-1221.
10. Dennison, S. M., et al. 2011. Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens. J. Virol. 85:1340-1347.
11. Dennison, S. M., et al. 2009. Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions. J. Virol. 83:10211-10223.
12. Frey, G., et al. 2010. Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nat. Struct. Mol. Biol. 17:1486-1491.
13. Frey, G., et al. 2008. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc. Natl. Acad. Sci. U. S. A. 105:3739-3744.
14. Friedman, D. F., P. Kraj, and L. E. Silberstein. 1995. VH4.21 expression in the normal human B-cell repertoire. Ann. N. Y. Acad. Sci. 764:285-292.
15. Gray, E. S., et al. 2009. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype Cinfected blood donors. J. Virol. 83:8925-8937.
16. Haynes, B. F., et al. 2005. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308:1906-1908.
17. Haynes, B. F., M. A. Moody, L. Verkoczy, G. Kelsoe, and S. M. Alam. 2005. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum. Antibodies 14:59-67.
18. Julien, J. P., et al. 2010. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding. J. Virol. 84:4136-4147.
19. Kohsaka, H., et al. 1996. The human immunoglobulin V(H) gene repertoire is genetically controlled and unaltered by chronic autoimmune stimulation. J. Clin. Invest. 98:2794-2800.
20. Kraj, P., D. F. Friedman, F. Stevenson, and L. E. Silberstein. 1995. Evidence for the overexpression of the VH4-34 (VH4.21) Ig gene segment in the normal adult human peripheral blood B cell repertoire. J. Immunol. 154:6406-6420.
21. Kwong, P. D., et al. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420:678-682.
22. Li, H., X. Cui, S. Pramanik, and N. O. Chimge. 2002. Genetic diversity of the human immunoglobulin heavy chain VH region. Immunol. Rev. 190:53-68.
23. Liao, H. X., et al. 2006. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353:268-282.
24. Matsuda, F., et al. 1998. The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus. J. Exp. Med. 188:2151-2162.
25. Muster, T., et al. 1993. A conserved neutralizing epitope on gp41 of human deficiency virus type 1. J. Virol. 67:6642-6647.
26. Nicely, N. I., et al. 2010. Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region. Nat. Struct. Mol. Biol. 17:1492-1494.
27. Ofek, G., et al. 2004. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78:10724-10737.
28. Ofek, G., et al. 2010. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J. Virol. 84:2955-2962.
29. Purtscher, M., et al. 1994. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 10:1651-1658.
30. Rabbitts, T. H., G. Matthyssens, and P. H. Hamlyn. 1980. Contribution of immunoglobulin heavy-chain variable-region genes to antibody diversity. Nature 284:238-243.
31. Richman, D. D., T. Wrin, S. J. Little, and C. J. Petropoulos. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 100:4144-4149.
32. Sather, D. N., et al. 2009. Factors associated with the development of crossreactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
33. Shen, X., et al. 2010. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. Proc. Natl. Acad. Sci. U. S. A. 107:5972-5977.
34. Shen, X., et al. 2009. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J. Virol. 83:3617-3625.
35. Shih, T. A., E. Meffre, M. Roederer, and M. C. Nussenzweig. 2002. Role of BCR affinity in T cell dependent antibody responses in vivo. Nat. Immunol. 3:570-575.
36. Shih, T. A., M. Roederer, and M. C. Nussenzweig. 2002. Role of antigen receptor affinity in T cell-independent antibody responses in vivo. Nat. Immunol. 3:399-406.
37. Song, L., et al. 2009. Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface. Proc. Natl. Acad. Sci. U. S. A. 106:9057-9062.
38. Stewart, A. K., C. Huang, B. D. Stollar, and R. S. Schwartz. 1993. Highfrequency representation of a single VH gene in the expressed human B cell repertoire. J. Exp. Med. 177:409-418.
39. Tomlinson, I. M., et al. 1995. A complete map of the human immunoglobulin VH locus. Ann. N. Y. Acad. Sci. 764:43-46.
40. Veijola, R., et al. 1996. The immunoglobulin heavy-chain variable region in insulin-dependent diabetes mellitus: affected-sib-pair analysis and association studies. Am. J. Hum. Genet. 59:462-470.
41. Vencovsky, J., R. A. Mageed, W. E. Ollier, and R. N. Maini. 1995. Monozygotic rheumatoid arthritis twin pairs express similar levels of conserved immunoglobulin V gene in polyclonal rheumatoid factors irrespective of disease status. Scand. J. Immunol. 42:147-157.
42. Verkoczy, L., et al. 2010. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc. Natl. Acad. Sci. U. S. A. 107:181-186.
43. Walker, L. W., et al. 2010. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6:1-14.
44. Wei, X., et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
45. Wood, N. W., et al. 1995. Susceptibility to multiple sclerosis and the immunoglobulin heavy chain variable region. J. Neurol. 242:677-682.
46. Xiao, X., et al. 2009. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 390:404-409.
47. Yang, P. M., et al. 1990. Possible deletion of a developmentally regulated heavy-chain variable region gene in autoimmune diseases. Proc. Natl. Acad. Sci. U. S. A. 87:7907-7911.
48. Zwick, M. B., et al. 2005. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 79:1252-1261.